These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 34854280)

  • 1. Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas.
    Candon S; Lemee V; Leveque E; Etancelin P; Paquin C; Carette M; Contentin N; Bobee V; Alani M; Cardinael N; Lepretre S; Camus V; Bouclet F; Boulet E; Menard AL; Lanic H; Stamatoullas A; Lemasle E; Pepin LF; Richard D; Dubois S; Tilly H; Dalleac A; Plantier JC; Etienne M; Jardin F
    Haematologica; 2022 Mar; 107(3):755-758. PubMed ID: 34854280
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.
    Marchesi F; Pimpinelli F; Giannarelli D; Ronchetti L; Papa E; Falcucci P; Pontone M; Di Domenico EG; di Martino S; Laquintana V; Mandoj C; Conti L; Cordone I; La Malfa A; Viggiani C; Renzi D; Palombi F; Romano A; Pisani F; Gumenyuk S; Di Bella O; Vujovic B; Morrone A; Ciliberto G; Ensoli F; Mengarelli A
    Leukemia; 2022 Feb; 36(2):588-590. PubMed ID: 34545184
    [No Abstract]   [Full Text] [Related]  

  • 3. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
    Gurion R; Rozovski U; Itchaki G; Gafter-Gvili A; Leibovitch C; Raanani P; Ben-Zvi H; Szwarcwort M; Taylor-Abigadol M; Dann EJ; Horesh N; Inbar T; Tzoran I; Lavi N; Fineman R; Ringelstein-Harlev S; Horowitz NA
    Haematologica; 2022 Mar; 107(3):715-720. PubMed ID: 34320790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination.
    Inaba T; Okumura K; Maekura C; Muramatsu A; Kobayashi T; Kuroda J; Nukui Y
    Int J Hematol; 2022 Jun; 115(6):913-914. PubMed ID: 35412265
    [No Abstract]   [Full Text] [Related]  

  • 5. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
    Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
    Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.
    Avivi I; Luttwak E; Saiag E; Halperin T; Haberman S; Sarig A; Levi S; Aharon A; Herishanu Y; Perry C
    Br J Haematol; 2022 Mar; 196(6):1329-1333. PubMed ID: 35075635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.
    Romero-Olmedo AJ; Schulz AR; Hochstätter S; Das Gupta D; Virta I; Hirseland H; Staudenraus D; Camara B; Münch C; Hefter V; Sapre S; Krähling V; Müller-Kräuter H; Widera M; Mei HE; Keller C; Lohoff M
    Nat Microbiol; 2022 Feb; 7(2):195-199. PubMed ID: 35013593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.
    Re D; Seitz-Polski B; Brglez V; Carles M; Graça D; Benzaken S; Liguori S; Zahreddine K; Delforge M; Bailly-Maitre B; Verrière B; Chamorey E; Barrière J
    Nat Commun; 2022 Feb; 13(1):864. PubMed ID: 35165284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy.
    Cohen D; Hazut Krauthammer S; Cohen YC; Perry C; Avivi I; Herishanu Y; Even-Sapir E
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3540-3549. PubMed ID: 33966088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decline of immune humoral response after BNT162b2 vaccine.
    Ferri S; Polidoro A; Ciacciarelli M; Ceratti U; Congedo V; Mele M; Coluzzi G; Spagnoli A; Iuliano L
    J Infect; 2022 Apr; 84(4):e34-e35. PubMed ID: 35183610
    [No Abstract]   [Full Text] [Related]  

  • 14. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
    Bagacean C; Letestu R; Al-Nawakil C; Brichler S; Lévy V; Sritharan N; Delmer A; Dartigeas C; Leblond V; Roos-Weil D; Tomowiak C; Merabet F; Béné MC; Clavert A; Chaoui D; Genet P; Guieze R; Laribi K; Drénou B; Willems L; Puppinck C; Legendre H; Troussard X; Malartre S; Cymbalista F; Michallet AS
    Blood Adv; 2022 Jan; 6(1):207-211. PubMed ID: 34844264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
    Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
    Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.
    Stankov MV; Hoffmann M; Gutierrez Jauregui R; Cossmann A; Morillas Ramos G; Graalmann T; Winter EJ; Friedrichsen M; Ravens I; Ilievska T; Ristenpart J; Schimrock A; Willenzon S; Ahrenstorf G; Witte T; Förster R; Kempf A; Pöhlmann S; Hammerschmidt SI; Dopfer-Jablonka A; Behrens GMN
    Lancet Infect Dis; 2024 Jan; 24(1):e1-e3. PubMed ID: 37995739
    [No Abstract]   [Full Text] [Related]  

  • 17. Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19.
    Chivu-Economescu M; Bleotu C; Grancea C; Chiriac D; Botezatu A; Iancu IV; Pitica I; Necula LG; Neagu A; Matei L; Dragu D; Sultana C; Radu EL; Nastasie A; Voicu O; Ataman M; Nedeianu S; Mambet C; Diaconu CC; Ruta SM
    J Cell Mol Med; 2022 Feb; 26(4):1293-1305. PubMed ID: 35043552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals.
    Al-Sadeq DW; Shurrab FM; Ismail A; Amanullah FH; Thomas S; Aldewik N; Yassine HM; Abdul Rahim HF; Abu-Raddad L; Nasrallah GK
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34888670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
    Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
    Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.